Publications

2021

  1. Palmroth, M, Kuuliala, K, Peltomaa, R, Virtanen, A, Kuuliala, A, Kurttila, A et al.. Tofacitinib Suppresses Several JAK-STAT Pathways in Rheumatoid Arthritis In Vivo and Baseline Signaling Profile Associates With Treatment Response. Front Immunol. 2021;12 :738481. doi: 10.3389/fimmu.2021.738481. PubMed PMID:34630419 PubMed Central PMC8498592.
  2. Palmroth, M, Viskari, H, Seppänen, MRJ, Keskitalo, S, Virtanen, A, Varjosalo, M et al.. IRF2BP2 Mutation Is Associated with Increased STAT1 and STAT5 Activation in Two Family Members with Inflammatory Conditions and Lymphopenia. Pharmaceuticals (Basel). 2021;14 (8):. doi: 10.3390/ph14080797. PubMed PMID:34451894 PubMed Central PMC8402006.
  3. Raivola, J, Haikarainen, T, Abraham, BG, Silvennoinen, O. Janus Kinases in Leukemia. Cancers (Basel). 2021;13 (4):. doi: 10.3390/cancers13040800. PubMed PMID:33672930 PubMed Central PMC7918039.

Search PubMed

2020

  1. Pastore, F, Krishnan, A, Hammarén, HM, Silvennoinen, O, Yan, B, Levine, RL et al.. JAK2S523L, a novel gain-of-function mutation in a critical autoregulatory residue in JAK2V617F- MPNs. Blood Adv. 2020;4 (18):4554-4559. doi: 10.1182/bloodadvances.2019001283. PubMed PMID:32956452 PubMed Central PMC7509885.

Search PubMed

2019

  1. Raivola, J, Haikarainen, T, Silvennoinen, O. Characterization of JAK1 Pseudokinase Domain in Cytokine Signaling. Cancers (Basel). 2019;12 (1):. doi: 10.3390/cancers12010078. PubMed PMID:31892268 PubMed Central PMC7016850.
  2. Gadina, M, Le, MT, Schwartz, DM, Silvennoinen, O, Nakayamada, S, Yamaoka, K et al.. Janus kinases to jakinibs: from basic insights to clinical practice. Rheumatology (Oxford). 2019;58 (Suppl 1):i4-i16. doi: 10.1093/rheumatology/key432. PubMed PMID:30806710 PubMed Central PMC6657570.
  3. T Virtanen, A, Haikarainen, T, Raivola, J, Silvennoinen, O. Selective JAKinibs: Prospects in Inflammatory and Autoimmune Diseases. BioDrugs. 2019;33 (1):15-32. doi: 10.1007/s40259-019-00333-w. PubMed PMID:30701418PubMed Central PMC6373396.
  4. Hammarén, HM, Virtanen, AT, Abraham, BG, Peussa, H, Hubbard, SR, Silvennoinen, O et al.. Janus kinase 2 activation mechanisms revealed by analysis of suppressing mutations. J Allergy Clin Immunol. 2019;143 (4):1549-1559.e6. doi: 10.1016/j.jaci.2018.07.022. PubMed PMID:30092288 PubMed Central PMC6363912.
  5. Hammarén, HM, Virtanen, AT, Raivola, J, Silvennoinen, O. The regulation of JAKs in cytokine signaling and its breakdown in disease. Cytokine. 2019;118 :48-63. doi: 10.1016/j.cyto.2018.03.041. PubMed PMID:29685781 .

Search PubMed

2018

  1. Raivola, J, Hammarén, HM, Virtanen, AT, Bulleeraz, V, Ward, AC, Silvennoinen, O et al.. Hyperactivation of Oncogenic JAK3 Mutants Depend on ATP Binding to the Pseudokinase Domain. Front Oncol. 2018;8 :560. doi: 10.3389/fonc.2018.00560. PubMed PMID:30560087 PubMed Central PMC6287396.
  2. Hammarén, HM, Virtanen, AT, Abraham, BG, Peussa, H, Hubbard, SR, Silvennoinen, O et al.. Janus kinase 2 activation mechanisms revealed by analysis of suppressing mutations. J Allergy Clin Immunol. 2019;143 (4):1549-1559.e6. doi: 10.1016/j.jaci.2018.07.022. PubMed PMID:30092288 PubMed Central PMC6363912.
  3. Hammarén, HM, Virtanen, AT, Raivola, J, Silvennoinen, O. The regulation of JAKs in cytokine signaling and its breakdown in disease. Cytokine. 2019;118 :48-63. doi: 10.1016/j.cyto.2018.03.041. PubMed PMID:29685781 .
  4. Ranta, N, Valli, A, Grönholm, A, Silvennoinen, O, Isomäki, P, Pesu, M et al.. Proprotein convertase enzyme FURIN is upregulated in primary Sjögren’s syndrome. Clin Exp Rheumatol. ;36 Suppl 112 (3):47-50. . PubMed PMID:29465367 .
  5. Fu, X, Zhang, C, Meng, H, Zhang, K, Shi, L, Cao, C et al.. Oncoprotein Tudor-SN is a key determinant providing survival advantage under DNA damaging stress. Cell Death Differ. 2018;25 (9):1625-1637. doi: 10.1038/s41418-018-0068-9. PubMed PMID:29459768 PubMed Central PMC6143532.

Search PubMed

2017

  1. Puleo, DE, Kucera, K, Hammarén, HM, Ungureanu, D, Newton, AS, Silvennoinen, O et al.. Identification and Characterization of JAK2 Pseudokinase Domain Small Molecule Binders. ACS Med Chem Lett. 2017;8 (6):618-621. doi: 10.1021/acsmedchemlett.7b00153. PubMed PMID:28626521 PubMed Central PMC5467198.
  2. Saarimäki-Vire, J, Balboa, D, Russell, MA, Saarikettu, J, Kinnunen, M, Keskitalo, S et al.. An Activating STAT3 Mutation Causes Neonatal Diabetes through Premature Induction of Pancreatic Differentiation. Cell Rep. 2017;19 (2):281-294. doi: 10.1016/j.celrep.2017.03.055. PubMed PMID:28402852 .

Search PubMed

2016

  1. Pertovaara, M, Silvennoinen, O, Isomäki, P. Cytokine-induced STAT1 activation is increased in patients with primary Sjögren’s syndrome. Clin Immunol. 2016;165 :60-7. doi: 10.1016/j.clim.2016.03.010. PubMed PMID:26995659 .

Search PubMed